Latest News
Announcements, partnerships, and milestones from the PointFit team.
Seveno Capital's strategic investment values PointFit at US $10 million, backing our non-invasive sweat patch for real-time biomarker monitoring beyond heart-rate wearables. The deal anchors Seveno's Hong Kong expansion and supports continuous lactate monitoring for athletes, with a modular platform built to scale across performance, metabolic health, and longevity care.
Privacy policy These statements have not been evaluated by the FDA. PointFit Sweat Sensor is not intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease.